Navigation Links
Latest advances in gene therapy for ocular disease are highlighted in Human Gene Therapy
Date:5/9/2011

the rate of retinal degeneration in "AAV Delivery of Wild-Type Rhodopsin Preserves Retinal Function in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa."

In the Brief Report "Gene Therapy in Ophthalmology: Validation on Cultured Retinal Cells and Explants from Postmortem Human Eyes," Fradot and colleagues show how gene therapy strategies can be developed and refined using cultured cells and explants from human eyes harvested after death to limit research studies done in primates.

"The most dramatic clinical success of in vivo gene therapy has been realized using AAV vectors in the treatment of a rare inherited form of congenital blindness; some level of functional improvement was realized in three independent trials. A number of scientists from around the world are progressing in vivo gene therapy into a number of other ocular disorders. This issue of the Journal captures some of these exiting new directions," says James M. Wilson, M.D., Ph.D., Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Humpback whale songs spread eastward like the latest pop tune
2. Latest report on North American industrial pollution reveals impacts on our shared water environment
3. Latest hands-free electronic water faucets found to be hindrance, not help, in infection control
4. New Brain Connectivity journal captures latest advances in neuroscience research
5. 1,500 worldwide experts debate the latest advances in breast pathologies treatments in Valencia
6. Stanford pollster to discuss latest survey on global warming
7. Survey reports latest honey bee losses
8. Latest research on GI health presented at DDW 2010
9. Database gives access to the latest findings about the tree of life
10. New edition of popular lab manual presents latest techniques for probing cellular dynamics
11. Latest analysis confirms suboptimal vitamin D levels in millions of US children
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Latest advances in gene therapy for ocular disease are highlighted in Human Gene Therapy
(Date:4/17/2014)... fish consumption advisories for expecting mothers are ineffective ... persistent organic pollutants (POPs). , The study, ... of Toronto Scarborough PhD student Matt Binnington and ... of environmental contamination, a mother,s compliance with advisories, ... influenced exposure in her children. , Their model ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... soon be able to make pest insects buzz off for ... all thanks to a tiny finding with enormous potential. ... Pune, India, is the senior author of a study that ... National Academy of Sciences , also called PNAS. Her work ...
... the University of Leeds have come a step closer to ... Their findings, published in the International Journal of Cancer ... to tackle other cancers should be considered as a future ... tamoxifen, that target a protein responsible for tumour growth, have ...
... , This release is available in German ... geneticists no longer dismiss out of hand his belief that ... published his book on evolution, Lamarck,s theory of transformation went ... decade, we have learned that the environment can after all ...
Cached Biology News:From protein to planes and pigskin 2From protein to planes and pigskin 3Another step toward resisting breast cancer 2Epigenetic changes don't last 2Epigenetic changes don't last 3Epigenetic changes don't last 4
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly to ... time period, doctors did not know that they needed to ... of vulnerable patients. In the same way, medical interns and ... transmitting herpes viruses to their patients. The CBCD explains. , ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... BRISBANE, Calif., Aug. 7 InterMune, Inc. (Nasdaq: ... and President of InterMune, will present at the Canaccord Adams 29th ... 10:30 a.m. EDT. , , To access a ... may log on to the investor relations page of InterMune,s corporate ...
... YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- , , ... --2Q09 Net Income Attributable to Controlling Interest was $13.2 million or , ... $0.17 per Diluted Share--, ... American Oriental Bioengineering, Inc. (NYSE: AOB ), ("the Company" or,"AOBO"), ...
... , , EMERYVILLE, Calif., Aug. 6 ... it has agreed to sell an aggregate of four million shares of ... share and $200 million aggregate principal amount of its 4.00% convertible senior ... the underwriters 30-day options to purchase up to an additional 600,000 shares ...
Cached Biology Technology:American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 2American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 3American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 4American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 5American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 6American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 7American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 8Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3
supplied with 10x reaction buffer...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
Biology Products: